These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Clonal evolution of Philadelphia chromosome in acute myeloid leukemia after azacitidine treatment. Yogarajah M; Montgomery N; Matson M; Blanchard L; Frank C; Gallagher S; Pepin K; Vaught L; Muluneh B; Foster MC; Zeidner JF Leuk Lymphoma; 2018 Dec; 59(12):3010-3012. PubMed ID: 29749763 [No Abstract] [Full Text] [Related]
3. Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysis. de Botton S; Brandwein JM; Wei AH; Pigneux A; Quesnel B; Thomas X; Legrand O; Recher C; Chantepie S; Hunault-Berger M; Boissel N; Nehme SA; Frattini MG; Tosolini A; Marion-Gallois R; Wang JJ; Cameron C; Siddiqui M; Hutton B; Milkovich G; Stein EM Cancer Med; 2021 Sep; 10(18):6336-6343. PubMed ID: 34427990 [TBL] [Abstract][Full Text] [Related]
4. Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial. DiNardo CD; Schuh AC; Stein EM; Montesinos P; Wei AH; de Botton S; Zeidan AM; Fathi AT; Kantarjian HM; Bennett JM; Frattini MG; Martin-Regueira P; Lersch F; Gong J; Hasan M; Vyas P; Döhner H Lancet Oncol; 2021 Nov; 22(11):1597-1608. PubMed ID: 34672961 [TBL] [Abstract][Full Text] [Related]
5. Enasidenib, a targeted inhibitor of mutant IDH2 proteins for treatment of relapsed or refractory acute myeloid leukemia. Stein EM Future Oncol; 2018 Jan; 14(1):23-40. PubMed ID: 29243965 [TBL] [Abstract][Full Text] [Related]
6. Abrupt evolution of Philadelphia chromosome-positive acute myeloid leukemia in myelodysplastic syndrome. Fukunaga A; Sakoda H; Iwamoto Y; Inano S; Sueki Y; Yanagida S; Arima N Eur J Haematol; 2013 Mar; 90(3):245-9. PubMed ID: 23240925 [TBL] [Abstract][Full Text] [Related]
7. Enasidenib for patients with relapsed acute myeloid leukemia and the IDH2 mutation. DiNardo C Clin Adv Hematol Oncol; 2018 Apr; 16(4):247-249. PubMed ID: 29742078 [No Abstract] [Full Text] [Related]
11. BCR-ABL1(+) acute myeloid leukemia: clonal selection of a BCR-ABL1(-) subclone as a cause of refractory disease with nilotinib treatment. Neuendorff NR; Schwarz M; Hemmati P; Türkmen S; Bommer C; Burmeister T; Dörken B; le Coutre P; Arnold R; Westermann J Acta Haematol; 2015; 133(2):237-41. PubMed ID: 25401297 [TBL] [Abstract][Full Text] [Related]
12. Enasidenib for the treatment of acute myeloid leukemia. Dugan J; Pollyea D Expert Rev Clin Pharmacol; 2018 Aug; 11(8):755-760. PubMed ID: 29770715 [TBL] [Abstract][Full Text] [Related]
13. Enasidenib: First Mutant IDH2 Inhibitor for the Treatment of Refractory and Relapsed Acute Myeloid Leukemia. Dogra R; Bhatia R; Shankar R; Bansal P; Rawal RK Anticancer Agents Med Chem; 2018; 18(14):1936-1951. PubMed ID: 30360730 [TBL] [Abstract][Full Text] [Related]
14. Teenage mutant neutrophilic precursors: Leukemia cutis with IDH2 mutation on enasidenib therapy. Kallen ME; Koka R; Singh Z; Sanchez-Petitto G; Zaman QU; Yared JA; Duong VH Leuk Res; 2020 Sep; 96():106406. PubMed ID: 32604058 [No Abstract] [Full Text] [Related]
15. Overview: A New Era of Cancer Genome in Myeloid Malignancies. Kiyoi H Oncology; 2015; 89 Suppl 1():1-3. PubMed ID: 26551625 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic/Pharmacodynamic Evaluation of Ivosidenib or Enasidenib Combined With Intensive Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed IDH1/2-Mutant Acute Myeloid Leukemia. Fan B; Chen Y; Yin F; Hua L; Almon C; Nabhan S; Cooper M; Yang H; Hossain M Clin Pharmacol Drug Dev; 2022 Apr; 11(4):429-441. PubMed ID: 35166065 [TBL] [Abstract][Full Text] [Related]
17. Enasidenib-induced eosinophilic differentiation in a patient with acute myeloid leukaemia with IDH2 and U2AF1 mutations. Galeotti J; Coombs CC Br J Haematol; 2019 Feb; 184(4):496. PubMed ID: 30334576 [No Abstract] [Full Text] [Related]
18. Spontaneous remission and clonal evolution in lenalidomide associated secondary AML. Waller DD; Monczak Y; Michel RP; Shustik C; Sebag M Leuk Lymphoma; 2020 Jul; 61(7):1724-1727. PubMed ID: 32077352 [No Abstract] [Full Text] [Related]
19. Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis. Norsworthy KJ; Mulkey F; Scott EC; Ward AF; Przepiorka D; Charlab R; Dorff SE; Deisseroth A; Kazandjian D; Sridhara R; Beaver JA; Farrell AT; de Claro RA; Pazdur R Clin Cancer Res; 2020 Aug; 26(16):4280-4288. PubMed ID: 32393603 [TBL] [Abstract][Full Text] [Related]